Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
2024 · New England Journal of Medicine · 165 citations
https://doi.org/10.1056/nejmoa2405888
R
Ryan Jacobs
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
160
Papers
2.3K
Citations
22
h-index
46
i10-index
Ryan Jacobs is an academic researcher from Levine Cancer Institute. The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment & CAR-T cell therapy research. The author has an h-index of 22, co-authored 136 publications.
ORCID: 0000-0001-7814-7959Papers by this author
worksOutcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 2 citations
https://doi.org/10.1016/s2152-2650(24)00564-0
CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
2024 · Clinical Lymphoma Myeloma & Leukemia · 1 citations
https://doi.org/10.1016/s2152-2650(24)01258-8
POSTER: ABCL-1113 Safety and Efficacy of AZD0486, a CD19 × CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2025 · Clinical Lymphoma Myeloma & Leukemia · 0 citations
https://doi.org/10.1016/s2152-2650(25)01063-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat